On April 21, 2026 Foundation Medicine, Inc., a global precision medicine company, reported an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOneCDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. The expansion broadens Foundation Medicine’s longstanding relationship in advancing biomarker-driven therapies with Bristol Myers Squibb.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Homozygous deletion is a major cause of MTAP deficiency.1 Copy number calling can have low signal-to-noise ratio, making the alterations challenging to accurately identify. FoundationOne CDx is a tissue-based next-generation sequencing test approved by the FDA to detect copy number loss. Accurate reporting of homozygous deletion can help identify eligible patients for targeted therapies.

"Homozygous MTAP deletion is a critical biomarker, yet one that can be difficult to detect without an assay that unveils blind spots others interpret as noise," said Troy Schurr, chief commercial officer at Foundation Medicine. "Foundation Medicine has approved companion diagnostic indications across all four major classes of genomic alterations and works with biopharmaceutical companies to support biomarker-driven therapy development. We look forward to collaborating with partners to help more patients benefit from advancements in precision oncology."

(Press release, Foundation Medicine, APR 21, 2026, View Source [SID1234664649])